Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine
NCT01353534
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
276
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
BIOLOGICAL:
A/H5N1 Antigen
DRUG:
Vaccine Enhancement Patch
Sponsor
Intercell USA, Inc.